Why Is CASI Pharmaceuticals, Inc. Ordinary Shares (CASI) Stock Down 67.1% Today?

CASI Pharmaceuticals (CASI) stock tanked 67.1% to $0.2594 per share on June 27, 2024, after announcing a buyout offer for its China business operations. The biotech firm's shares traded 3.73M copies—190.7x the 30-day average of 19,535 shares—signaling panic selling across retail and institutional holders. Previous close: $0.80. The move answers why is CASI stock down today: management is selling off a major geographic revenue segment, and the market is punishing the valuation hit with extreme prejudice.

This isn't a traditional earnings miss or product failure. This is a capital structure event.

What's Driving CASI Stock Down Today

The primary catalyst is the announcement of a buyout offer for CASI's China business. In biotech, when a company puts a major geographic segment on the block, it signals distress: either cash burn is accelerating, the core U.S. pipeline isn't delivering, or both. CASI's China operations have been a revenue engine, and losing that segment means the company's top-line shrinks materially while cash continues to drain.

The 67.1% crater reflects the market's pricing of multiple negative scenarios simultaneously:

\n
• Cash runway compression: If CASI is divesting a profitable segment, they need cash now, not later. This suggests the burn rate is unsustainable at current spending.
\n
• Valuation reset downward: Selling China removes a growth vector. The company goes from a diversified biotech with U.S. and China exposure to a pure-play U.S. oncology play with a thinner balance sheet.
\n
• Execution risk: Management credibility takes a hit. Investors who bought CASI for the two-geography strategy now watch that thesis implode.
\n
• Dilution probability: If the China sale doesn't generate enough cash, CASI will likely need to raise capital through equity offerings, crushing current shareholders.
\n

CASI's core asset—EVOMELA (melphalan for injection)—is an established conditioning therapy for autologous stem-cell transplant patients in hematologic malignancies. Revenue from this product should provide some cushion, but the China business was likely contributing 30-50% of topline. Losing it is a gut punch.

For context, small-cap biotech companies trading below $1 per share are often in distress mode. CASI crossed that threshold today. Peer comparisons: most profitable oncology biotech firms trade 3-6x revenue multiples. CASI's market cap just collapsed to near $0.0B, suggesting the market sees minimal value in the remaining U.S.-only business.

CASI Stock Key Levels to Watch

Current price: $0.2594. Day range: $0.2368 to $0.3749. Previous close: $0.8000.

Support levels:

\n
• $0.24 (intraday low, panic support)
\n
• $0.20 (round number, psychological floor for penny stocks)
\n
• $0.15 (50% of today's close—watch for institutional stop-loss triggers here)
\n

Resistance levels:

\n
• $0.35 (intraday high, first bounce target)
\n
• $0.50 (50% recovery of the crash, unlikely but watch for short-covering)
\n
• $0.80 (previous close, the "reset" level—only reached if deal fails or new catalyst emerges)
\n

The 52-week high is not listed in available data, but trading context suggests CASI has been under pressure for months. Today's move is a climactic event, not a gradual decline. Moving average positioning is irrelevant for a stock this volatile—traditional technical analysis breaks down at penny-stock levels.

Volume tells the real story: 3.73M shares traded vs. a 30-day average of 19,535. This is a 190.7x spike. Panic liquidity like this typically marks capitulation. The next 2-3 days will show whether buyers step in at $0.24-$0.20 or if the sell-off cascades further. Insider buying or short-covering rallies could trigger relief bounces, but they won't restore confidence until management addresses cash runway.

What Analysts Say About CASI Stock

HC Wainwright & Co. maintained a Buy rating on CASI as of November 2023, but that thesis is now severely compromised. The firm's bullish stance was likely based on EVOMELA sales growth and China expansion—both of which are now in question.

Current consensus data is limited due to the recency of today's announcement, but expect analyst reviews to cascade in over the next 48 hours. Look for downgrades from any firm that was bullish on the company's diversified geographic footprint. The real tell: if any analyst reduces their price target below $0.50, the market is pricing execution risk on the China sale itself.

Prior to today's crash, CASI was likely trading at a discount to its intrinsic U.S.-only value, suggesting weak institutional coverage. Now that the stock is sub-$0.30, most sell-side analysts will drop coverage entirely—biotech shops don't like trading below $1 due to regulatory and reputational issues.

For retail investors: consensus targets are meaningless when a company is in distress. Focus instead on cash runway calculations and whether the China sale closes at a valuation that extends the runway beyond 12 months.

What's Next for CASI Pharmaceuticals Stock

Next catalyst #1 – China business sale closing: This is the single most important event. When will the buyer's due diligence complete? Will the sale price match expectations? If CASI gets less cash than anticipated, additional dilution becomes certain.

Next catalyst #2 – Q2 2024 earnings and cash position update: Likely in August. This will reveal exact cash burn rates and remaining runway. If the company guides to less than 18 months of cash remaining, the stock could trade lower.

Next catalyst #3 – EVOMELA sales trends: The core product must deliver growth. If Q2 EVOMELA sales disappoint, the China divestiture story becomes much grimmer.

Bull case: The China buyer pays a premium valuation. CASI uses proceeds to fund 24+ months of EVOMELA commercialization. U.S. oncology sales accelerate. Stock rebounds to $0.60-$0.80 within 12 months. Price target: $1.00 by end of 2025 (highly speculative).

Bear case: The China sale generates minimal proceeds. CASI announces equity offering within 60 days. Shareholders get diluted 40-60%. Stock trades to $0.10-$0.15. Company eventually merges or gets acquired at a steep discount. Price target: $0.05-$0.10 within 6 months.

The risk/reward is asymmetric to the downside. Current holders are already down 67% today. Further dilution could knock another 50-70% off the stock. New buyers should only nibble if they have a 24-month horizon and high risk tolerance. This is not a recovery play—this is a restructuring story with execution risk on both the sale and the remaining business.

Frequently Asked Questions

Why is CASI stock down today?
CASI announced a buyout offer for its China business operations, a major revenue segment. The market is pricing in cash compression, valuation reset, and likely equity dilution. The 67.1% crash on 190.7x average volume reflects panic selling as investors flee distress-mode biotech.

Is CASI stock a buy right now?
Not for risk-averse investors. The company is in restructuring mode with uncertain cash runway. Only traders with high risk tolerance and a 24-month horizon should consider nibbling at support levels like $0.20-$0.24. Fundamental investors should wait for the China sale to close and Q2 earnings to clarify the path forward. This is a \"show me\" story, not a \"buy and hold\" story.

What is CASI stock price target?
HC Wainwright's last recorded target was bullish pre-announcement. New targets will emerge over the next week as analysts reassess. Expect price targets between $0.15-$0.40 from remaining analysts. Ignore pre-announcement targets—they're worthless in a restructuring event.

What happened to CASI's China business?
CASI received a buyout offer for its China operations and is pursuing the sale. The company likely decided that maintaining two geographic segments with limited cash was unsustainable. Selling China frees up management resources and provides a one-time cash infusion, but it permanently reduces future revenue potential.

How much cash does CASI have left?
Not disclosed in the announcement. This is the critical unknown. Investors must wait for Q2 earnings and management guidance (expected August 2024) to model cash runway. If the company guides to less than 12 months of cash remaining, dilution is almost certain. If 18-24 months, there's a chance to stabilize the business.